Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2016 /
Updates in prostate and bladder cancer therapy

8th - 10th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.07.16
Views: 1860
Rating:

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Dr Petrylak speaks with ecancertv at the Best of ASCO 2016 about novel therapies to treat prostate and bladder cancers.

In prostate cancer, he describes studies which find lower doses of docetaxel are equivalent in overall survival to higher doses of cabazitaxel.

Dr Petrylak also considers immunotherapy developments against bladder cancer, including checkpoint inhibitors and two new monoclonal antibodies.

For more on atezolizumab to treat bladder cancer, we spoke to Dr Arjun Balar.

Also available is our expert review of advances in prostate cancer from ASCO 2016.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation